Literature DB >> 18409077

Multiple brain infarctions induced by imatinib mesylate in a patient with clonal eosinophilia.

Eriko Sato1, Koichi Sugimoto2, Yasuharu Hamano1, Yasushi Isobe1, Makoto Sasaki1, Junichi Tomomatsu1, Hideaki Nitta1, Kazuo Oshimi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18409077     DOI: 10.1007/s12185-008-0074-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

Review 1.  Eosinophil granule proteins and their role in disease.

Authors:  G M Walsh
Journal:  Curr Opin Hematol       Date:  2001-01       Impact factor: 3.284

Review 2.  Modern diagnosis and treatment of primary eosinophilia.

Authors:  A Tefferi
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

Review 3.  Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.

Authors:  Jason Gotlib
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

Review 4.  Practical management of patients with chronic myeloid leukemia receiving imatinib.

Authors:  Michael W N Deininger; Stephen G O'Brien; John M Ford; Brian J Druker
Journal:  J Clin Oncol       Date:  2003-03-13       Impact factor: 44.544

Review 5.  Imatinib: a targeted clinical drug development.

Authors:  Renaud Capdeville; Sandra Silberman
Journal:  Semin Hematol       Date:  2003-04       Impact factor: 3.851

6.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Authors:  Animesh Pardanani; Stephanie R Brockman; Sarah F Paternoster; Heather C Flynn; Rhett P Ketterling; Terra L Lasho; Ching-Liang Ho; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

7.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

Authors:  Animesh Pardanani; Terra Reeder; Luis F Porrata; Chin-Yang Li; Henry D Tazelaar; E Joanna Baxter; Thomas E Witzig; Nicholas C P Cross; Ayalew Tefferi
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.